The significance of SIRI and SII scores in predicting the effect of omalizumab treatment in patients with severe allergic asthma.

IF 2.1 4区医学 Q3 ALLERGY

Allergologia et immunopathologia Pub Date : 2025-07-01 eCollection Date: 2025-01-01 DOI:10.15586/aei.v53i4.1325

Sinem Berik Safçi, Özlem Erçen Diken, Sibel Kara, Tuğsan Serintürk

{"title":"The significance of SIRI and SII scores in predicting the effect of omalizumab treatment in patients with severe allergic asthma.","authors":"Sinem Berik Safçi, Özlem Erçen Diken, Sibel Kara, Tuğsan Serintürk","doi":"10.15586/aei.v53i4.1325","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the role of systemic inflammation response index (SIRI) and systemic immune-inflammation index (SII) biomarkers in predicting the response to omalizumab (OMA) treatment in patients with severe allergic asthma.Methods: A retrospective analysis was conducted to examine the correlation between the fourth-month treatment responses of patients undergoing OMA therapy for severe allergic asthma and their baseline neutrophil, lymphocyte, monocyte, and platelet values, as well as SIRI and SII scores.Results: Posttreatment asthma control scores had a positive correlation with baseline SIRI (p = 0.03, r = 0.358), SII (p = 0.04, r = 0.345), and serum neutrophil values (p = 0.01, r = 0.308), and a negative correlation with lymphocyte values (p = 0.00, r = -0.398). Baseline SII showed a negative correlation with posttreatment systemic steroid usage (mg) (p = 0.04, r = -0.247) and the number of exacerbations (p = 0.02, r = -0.269).Conclusion: SIRI and SII scores hold promise for predicting the success of OMA therapy; however, their utility needs to be validated in larger patient cohorts and further studies.","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 4","pages":"1-6"},"PeriodicalIF":2.1000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergologia et immunopathologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15586/aei.v53i4.1325","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the role of systemic inflammation response index (SIRI) and systemic immune-inflammation index (SII) biomarkers in predicting the response to omalizumab (OMA) treatment in patients with severe allergic asthma.

Methods: A retrospective analysis was conducted to examine the correlation between the fourth-month treatment responses of patients undergoing OMA therapy for severe allergic asthma and their baseline neutrophil, lymphocyte, monocyte, and platelet values, as well as SIRI and SII scores.

Results: Posttreatment asthma control scores had a positive correlation with baseline SIRI (p = 0.03, r = 0.358), SII (p = 0.04, r = 0.345), and serum neutrophil values (p = 0.01, r = 0.308), and a negative correlation with lymphocyte values (p = 0.00, r = -0.398). Baseline SII showed a negative correlation with posttreatment systemic steroid usage (mg) (p = 0.04, r = -0.247) and the number of exacerbations (p = 0.02, r = -0.269).

Conclusion: SIRI and SII scores hold promise for predicting the success of OMA therapy; however, their utility needs to be validated in larger patient cohorts and further studies.

查看原文本刊更多论文

SIRI和SII评分预测奥玛珠单抗治疗对严重过敏性哮喘患者疗效的意义

目的：评价全身炎症反应指数（SIRI）和全身免疫炎症指数（SII）生物标志物在预测奥玛珠单抗（OMA）治疗严重过敏性哮喘患者反应中的作用。方法：回顾性分析接受OMA治疗的严重过敏性哮喘患者第4个月治疗反应与其基线中性粒细胞、淋巴细胞、单核细胞和血小板值以及SIRI和SII评分的相关性。结果：治疗后哮喘控制评分与基线SIRI （p = 0.03, r = 0.358）、SII （p = 0.04, r = 0.345）、血清中性粒细胞值（p = 0.01, r = 0.308）呈正相关，与淋巴细胞值（p = 0.00, r = -0.398）呈负相关。基线SII与治疗后全身类固醇使用（mg）（p = 0.04, r = -0.247）和加重次数（p = 0.02, r = -0.269）呈负相关。结论：SIRI和SII评分有望预测OMA治疗的成功；然而，它们的效用需要在更大的患者群体和进一步的研究中得到验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Allergologia et immunopathologia 医学-过敏

CiteScore

3.70

自引率

0.00%

发文量

131

审稿时长

6-12 weeks

期刊介绍： Founded in 1972 by Professor A. Oehling, Allergologia et Immunopathologia is a forum for those working in the field of pediatric asthma, allergy and immunology. Manuscripts related to clinical, epidemiological and experimental allergy and immunopathology related to childhood will be considered for publication. Allergologia et Immunopathologia is the official journal of the Spanish Society of Pediatric Allergy and Clinical Immunology (SEICAP) and also of the Latin American Society of Immunodeficiencies (LASID). It has and independent international Editorial Committee which submits received papers for peer-reviewing by international experts. The journal accepts original and review articles from all over the world, together with consensus statements from the aforementioned societies. Occasionally, the opinion of an expert on a burning topic is published in the "Point of View" section. Letters to the Editor on previously published papers are welcomed. Allergologia et Immunopathologia publishes 6 issues per year and is included in the major databases such as Pubmed, Scopus, Web of Knowledge, etc.